BioNTech SE ADR [NASDAQ: BNTX] price surged by 0.06 percent to reach at $0.07.
The one-year BNTX stock forecast points to a potential downside of -6.87. The average equity rating for BNTX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on BioNTech SE ADR [BNTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNTX shares is $115.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNTX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for BioNTech SE ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 16, 2024. The new note on the price target was released on August 07, 2024, representing the official price target for BioNTech SE ADR stock.
The Average True Range (ATR) for BioNTech SE ADR is set at 5.42, with the Price to Sales ratio for BNTX stock in the period of the last 12 months amounting to 10.10. The Price to Book ratio for the last quarter was 1.44, with the Price to Cash per share for the same quarter was set at 46.78. Price to Free Cash Flow for BNTX in the course of the last twelve months was 9.82 with Quick ratio for the last quarter at 7.40.
BNTX Stock Performance Analysis:
BioNTech SE ADR [BNTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.82. With this latest performance, BNTX shares gained by 41.51% in over the last four-week period, additionally plugging by 33.51% over the last 6 months – not to mention a rise of 8.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNTX stock in for the last two-week period is set at 87.45, with the RSI for the last a single of trading hit 92.19, and the three-weeks RSI is set at 82.31 for BioNTech SE ADR [BNTX]. The present Moving Average for the last 50 days of trading for this stock 87.98, while it was recorded at 110.35 for the last single week of trading, and 92.88 for the last 200 days.
Insight into BioNTech SE ADR Fundamentals:
BioNTech SE ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.54.
BioNTech SE ADR [BNTX] Institutonal Ownership Details
The top three institutional holders of BNTX stocks are: BAILLIE GIFFORD & CO with ownership of 8.28 million shares, which is approximately 3.4408%. PRIMECAP MANAGEMENT CO/CA/, holding 4.79 million shares of the stock with an approximate value of $$384.89 million in BNTX stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $$351.94 million in BNTX stock with ownership which is approximately 1.8207%.
